BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 29462212)

  • 1. Epstein-Barr virus nuclear antigen EBNA-LP is essential for transforming naïve B cells, and facilitates recruitment of transcription factors to the viral genome.
    Szymula A; Palermo RD; Bayoumy A; Groves IJ; Ba Abdullah M; Holder B; White RE
    PLoS Pathog; 2018 Feb; 14(2):e1006890. PubMed ID: 29462212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.
    Pich D; Mrozek-Gorska P; Bouvet M; Sugimoto A; Akidil E; Grundhoff A; Hamperl S; Ling PD; Hammerschmidt W
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter.
    Peng R; Moses SC; Tan J; Kremmer E; Ling PD
    J Virol; 2005 Apr; 79(7):4492-505. PubMed ID: 15767449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus BamHI W repeat number limits EBNA2/EBNA-LP coexpression in newly infected B cells and the efficiency of B-cell transformation: a rationale for the multiple W repeats in wild-type virus strains.
    Tierney RJ; Kao KY; Nagra JK; Rickinson AB
    J Virol; 2011 Dec; 85(23):12362-75. PubMed ID: 21957300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus protein EBNA-LP engages YY1 through leucine-rich motifs to promote naïve B cell transformation.
    Cable JM; Reinoso-Vizcaino NM; White RE; Luftig MA
    bioRxiv; 2024 Jan; ():. PubMed ID: 38260266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic analysis of the Epstein-Barr virus-coded leader protein EBNA-LP as a co-activator of EBNA2 function.
    McCann EM; Kelly GL; Rickinson AB; Bell AI
    J Gen Virol; 2001 Dec; 82(Pt 12):3067-3079. PubMed ID: 11714985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining the role of the Epstein-Barr virus Cp EBNA2-dependent enhancer during the establishment of latency by using mutant and wild-type viruses recovered from cottontop marmoset lymphoblastoid cell lines.
    Yoo L; Speck SH
    J Virol; 2000 Dec; 74(23):11115-20. PubMed ID: 11070007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA Sequencing Analyses of Gene Expression during Epstein-Barr Virus Infection of Primary B Lymphocytes.
    Wang C; Li D; Zhang L; Jiang S; Liang J; Narita Y; Hou I; Zhong Q; Zheng Z; Xiao H; Gewurz BE; Teng M; Zhao B
    J Virol; 2019 Jul; 93(13):. PubMed ID: 31019051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EBNA2 and Its Coactivator EBNA-LP.
    Kempkes B; Ling PD
    Curr Top Microbiol Immunol; 2015; 391():35-59. PubMed ID: 26428371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Epstein-Barr virus BamHI C promoter is not essential for B cell immortalization in vitro, but it greatly enhances B cell growth transformation.
    Tierney RJ; Nagra J; Rowe M; Bell AI; Rickinson AB
    J Virol; 2015 Mar; 89(5):2483-93. PubMed ID: 25540367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
    Rowe M; Raithatha S; Shannon-Lowe C
    J Virol; 2014 Oct; 88(20):12065-76. PubMed ID: 25122803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) Proteins Regulate EBNA2 Binding to Distinct RBPJ Genomic Sites.
    Wang A; Welch R; Zhao B; Ta T; Keleş S; Johannsen E
    J Virol; 2015 Dec; 90(6):2906-19. PubMed ID: 26719268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
    Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.
    Wang C; Zhou H; Xue Y; Liang J; Narita Y; Gerdt C; Zheng AY; Jiang R; Trudeau S; Peng CW; Gewurz BE; Zhao B
    J Virol; 2018 May; 92(9):. PubMed ID: 29467311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residues 231 to 280 of the Epstein-Barr virus nuclear protein 2 are not essential for primary B-lymphocyte growth transformation.
    Harada S; Yalamanchili R; Kieff E
    J Virol; 1998 Dec; 72(12):9948-54. PubMed ID: 9811732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
    Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conserved regions in the Epstein-Barr virus leader protein define distinct domains required for nuclear localization and transcriptional cooperation with EBNA2.
    Peng R; Tan J; Ling PD
    J Virol; 2000 Nov; 74(21):9953-63. PubMed ID: 11024123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.
    Schlager S; Speck SH; Woisetschläger M
    J Virol; 1996 Jun; 70(6):3561-70. PubMed ID: 8648690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth.
    Zhao B; Zou J; Wang H; Johannsen E; Peng CW; Quackenbush J; Mar JC; Morton CC; Freedman ML; Blacklow SC; Aster JC; Bernstein BE; Kieff E
    Proc Natl Acad Sci U S A; 2011 Sep; 108(36):14902-7. PubMed ID: 21746931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B cells infected with Type 2 Epstein-Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection.
    Romero-Masters JC; Huebner SM; Ohashi M; Bristol JA; Benner BE; Barlow EA; Turk GL; Nelson SE; Baiu DC; Van Sciver N; Ranheim EA; Gumperz J; Sherer NM; Farrell PJ; Johannsen EC; Kenney SC
    PLoS Pathog; 2020 Feb; 16(2):e1008365. PubMed ID: 32059024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.